Odyssey Health, Inc., Enters the $26 Billion Breast Cancer Marketplace
Odyssey Health (OTCQB: ODYY) announced on October 16, 2025 that its subsidiary Odyssey Medical Devices signed a sub-licensing agreement for exclusive worldwide marketing and distribution rights to BreastCheck®, a non-invasive, at-home breast screening test with 15-minute results. The agreement is subject to closing conditions.
BreastCheck® is described as a first-line screening tool (not a mammogram replacement) and the technology is FDA registered in the United States and registered with relevant authorities in the European Union and the United Kingdom. Management expects near-term commercialization and initial revenue, signalling a move from development-stage to revenue-generating medtech.
Odyssey Health (OTCQB: ODYY) ha annunciato il 16 ottobre 2025 che la sua controllata Odyssey Medical Devices ha firmato un accordo di sub-licenza per i diritti mondiali esclusivi di commercializzazione e distribuzione di BreastCheck®, un test di screening al seno non invasivo da fare a casa con risultati in 15 minuti. L'accordo è soggetto a condizioni di chiusura.
BreastCheck® è descritto come uno strumento di screening di prima linea (non sostituisce una mammografia) e la tecnologia è registrata dalla FDA negli Stati Uniti e registrata presso le autorità competenti nell'Unione Europea e nel Regno Unito. La direzione prevede una commercializzazione a breve termine e entrate iniziali, segnalando il passaggio dalla fase di sviluppo a quella medtech che genera entrate.
Odyssey Health (OTCQB: ODYY) anunció el 16 de octubre de 2025 que su subsidiaria Odyssey Medical Devices firmó un acuerdo de sub-licencia para derechos exclusivos de comercialización y distribución mundial de BreastCheck®, una prueba de screening de mama no invasiva para hacer en casa con resultados en 15 minutos. El acuerdo está sujeto a condiciones de cierre.
BreastCheck® se describe como una herramienta de cribado de primera línea (no reemplaza a una mamografía) y la tecnología está registrada por la FDA en los Estados Unidos y registrada ante las autoridades pertinentes de la Unión Europea y del Reino Unido. La dirección espera una comercialización cercana y ingresos iniciales, lo que indica un paso de la etapa de desarrollo a una medtech que genera ingresos.
Odyssey Health (OTCQB: ODYY)는 2025년 10월 16일에 자회사 Odyssey Medical Devices가 BreastCheck®의 독점 글로벌 마케팅 및 유통 권리를 위한 재자격 서브라이선스 계약을 체결했다고 발표했습니다. 이 계약은 15분의 결과를 가진 비침습적 가정용 유방 검사 테스트입니다. 이 계약은 종결 조건의 subject입니다.
BreastCheck®는 1차 선별 도구로 설명되며(맥맨 검사를 대체하지 않음), 이 기술은 미국에서 FDA 등록되어 있고 유럽 연합과 영국의 관련 당국에도 등록되어 있습니다. 경영진은 단기간 내 상용화 및 초기 수익을 기대하며, 개발 단계에서 수익 창출 메드테크로의 전환을 시사합니다.
Odyssey Health (OTCQB: ODYY) a annoncé le 16 octobre 2025 que sa filiale Odyssey Medical Devices a signé un accord de sous-licence portant sur des droits mondiaux exclusifs de commercialisation et de distribution de BreastCheck®, un test de dépistage mammaire non invasif à réaliser à domicile, avec des résultats en 15 minutes. L'accord est soumis à des conditions de clôture.
BreastCheck® est décrit comme un outil de dépistage de première ligne (non destiné à remplacer une mammographie) et la technologie est enregistrée par la FDA aux États-Unis et enregistrée auprès des autorités compétentes de l'Union européenne et du Royaume-Uni. La direction prévoit une commercialisation à court terme et des revenus initiaux, signalant une transition de la phase de développement à une medtech générant des revenus.
Odyssey Health (OTCQB: ODYY) gab am 16. Oktober 2025 bekannt, dass seine Tochtergesellschaft Odyssey Medical Devices eine Unterlizenzvereinbarung für exklusive weltweite Vermarktungs- und Vertriebsrechte an BreastCheck® unterzeichnet hat, einen nicht-invasiven, zu Hause durchzuführenden Brustscreening-Test mit 15 Minuten Ergebnissen. Die Vereinbarung steht unter dem Vorbehalt der Abschlussbedingungen.
BreastCheck® wird als erstes Screening-Tool beschrieben (führt keine Mammografie ersetzen) und die Technologie ist FDA-registriert in den Vereinigten Staaten und bei den relevanten Behörden in der Europäischen Union und dem Vereinigten Königreich registriert. Das Management erwartet eine kurzfristige Kommerzialisierung und erste Umsätze, was einen Übergang von der Entwicklungsphase zu einer umsatzgenerierenden Medizintechnik signalisiert.
Odyssey Health (OTCQB: ODYY) أعلنت في 16 أكتوبر 2025 أن الشركة الفرعية Odyssey Medical Devices وقعت اتفاقية فرعية ترخيص ذات حقوق حصرية في العالم للتسويق والتوزيع لـ BreastCheck®، وهو فحص فحص الثدي غير جراحي يمكن إجراؤه في المنزل مع نتائج خلال 15 دقيقة. تخضع الصفقة لشروط الإغلاق.
وصف BreastCheck® بأنه أداة فحص من الخط الأول (لا يحل محل فحص الثدي الشعاعي) والتقنية مسجلة لدى FDA في الولايات المتحدة ومسجلة لدى السلطات المعنية في الاتحاد الأوروبي والمملكة المتحدة. يتوقع الإدارة التسويق في المدى القريب وإيرادات أولية، مما يشير إلى الانتقال من مرحلة التطوير إلى تقنيات طبية تحقق الإيرادات.
Odyssey Health (OTCQB: ODYY) 宣布于2025年10月16日，其子公司 Odyssey Medical Devices 已就 BreastCheck® 签订独家全球市场与分销权的再授权协议，该测试为非侵入性的居家乳房筛查，结果在15分钟内出具。该协议须完成条件。
BreastCheck® 被描述为一线筛查工具（不能替代乳腺X 光摄影），该技术在美国被 FDA 注册，并在欧盟和英国的相关当局注册。管理层预计在近期内实现商业化并取得初始收入，标志着从开发阶段向产生收入的医疗技术阶段的转变。
- Exclusive worldwide sublicensing rights for BreastCheck®
- BreastCheck® is FDA registered in the United States
- Regulatory registration reported in the EU and UK
- At-home test with 15-minute immediate results
- Definitive agreement is subject to closing conditions
- BreastCheck® is not a replacement for mammograms, limiting clinical role
- No quantified revenue, timeline, or commercial terms disclosed
Odyssey Medical Devices, Inc., a subsidiary of Odyssey Health Inc., to acquire exclusive global marketing and distribution rights for the BreastCheck®
LAS VEGAS, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTCQB: ODYY), a medical device company with a focus in life-saving medical solutions today announced that the company has signed a sub-licensing agreement for exclusive, worldwide rights to the BreastCheck®, a non-invasive test for breast abnormalities. The definitive agreement, managed through its subsidiary Odyssey Medical Devices, Inc., is subject to certain closing conditions.
The BreastCheck® test can be done at home and takes just 15 minutes. The results are immediate and BreastCheck® has been proven to be a reliable guide in the first stage identification of potential breast abnormalities. While BreastCheck® is not a replacement for a mammogram, it is an effective first line screening device. The technology behind BreastCheck® is FDA registered in the United States, and it is also registered with the relevant regulatory authorities in the European Union and the United Kingdom.
“This is a major step forward in our medical device portfolio. Early detection has significantly increased breast cancer survival rates in recent years. It is estimated that this year 317,000 new cases of invasive breast cancer will be diagnosed in women in the United States. Statistics show that 1 in 8 women in the United States will develop breast cancer in their lifetime,” said Michael Redmond, CEO of Odyssey. “The breast cancer diagnostics market is a rapidly growing sector, currently valued in the low tens of billions of dollars depending on what is included, with forecasts to double, or more, over the next 8-10 years. Growth is being driven by technological advances, such as imaging, AI, genomics, the rising incidence of breast cancer globally, greater emphasis on early detection, and expanding healthcare access especially in emerging markets.”
“We expect to begin commercialization and generate initial revenue from BreastCheck® in the near future, marking our transition from a development-stage to a revenue-generating medtech company,” commented Mr. Redmond.
About BreastCheck®
BreastCheck®, a product of Davion Healthcare PLC, is a safe, accurate and low-cost, way to routinely monitor for breast abnormalities and is intended to be an adjunct to established procedures for the detection of breast disease, such as clinical breast examination and mammography. Abnormalities within the breast frequently produce additional breast heat. BreastCheck® averages temperature at three areas on each breast. By comparing the temperature of corresponding areas of one breast to the other and entering the results on the BreastCheck® Mobile App, results can be interpreted immediately.
About Breast Cancer
Breast cancer is the most common cancer in women worldwide and a leading cause of cancer-related deaths. It occurs when abnormal cells in the breast grow uncontrollably, forming tumors that may spread to other parts of the body. The American Cancer Society estimates that in the United States about 316,950 invasive and 59,080 non-invasive cases are expected in 2025 and breast cancer accounts for roughly
About Odyssey Health, Inc.
Odyssey Health, Inc. (OTCQB: ODYY) is a medical technology company with a focus in the area of life- saving medical solutions. Odyssey’s corporate mission is to create, acquire and accumulate distinct assets, intellectual properties, and exceptional technologies that provide meaningful medical solutions The Company is focused on building and acquiring assets in areas that have an identified technological advantage, provide superior clinical utility, have a substantial market opportunity. Odyssey Medical Devices, Inc is a wholly owned subsidiary of Odyssey Health Inc.
For more information, visit: https://www.odysseyhealthinc.com/breastcheck
Forward-Looking Statements
This communication contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including without limitation statements regarding the ability of the Company to timely and successfully close on the sub-license agreement. These forward-looking statements are based on management’s beliefs and assumptions and information currently available. The words "believe," "expect," "anticipate," "intend," "estimate," "project" and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to: the Company’s ability to advance the development and commercialization of the BreastCheck® under the timelines and in accord with the milestones projected; the Company’s ability to raise capital and obtain funding, non-dilutive or otherwise, for the development and commercialization of the BreastCheck®; the Company’s ability to obtain, maintain and enforce necessary patent and other intellectual property protection; the Company’s expectations as to the outcome of the potential benefits, effectiveness and safety of the BreastCheck® including as to administration, manufacturing, distribution and general economic and market conditions and risks, as well as other uncertainties described in our filings with the U.S. Securities and Exchange Commission. All information set forth is as of the date hereof unless otherwise indicated. You should consider these factors in evaluating the forward-looking statements.
Media and Investors Contacts:
CG CAPITAL
Rich Cockrell
877.889.1972
investorrelations@cg.capital
FAQ
What did Odyssey Health (ODYY) announce on October 16, 2025 about BreastCheck®?
Is BreastCheck® approved by regulators for use in the United States and Europe?
How quickly does the BreastCheck® at-home test deliver results and what is its purpose?
When does Odyssey expect to commercialize BreastCheck® and generate revenue (ODYY)?
Does the BreastCheck® deal carry any closing or execution risks for Odyssey Health (ODYY)?
